D-SIMLAB Awarded S$500,000 Grant under SPRING Singapore's Technology Enterprise Commercialisation Scheme (TECS)
04 Jun 2009
Singapore, 4 June 2009 – D-SIMLAB Technologies Pte Ltd (“D-SIMLAB”), the
Singapore-headquartered leading provider of high-performance, simulation-based
decision support solutions for industries that invested in high value operating assets,
has been awarded up to S$500,000 grant from SPRING Singapore under the
Technology Enterprise Commercialisation Scheme (TECS).
TECS is a competitive grant and evaluated by investment professionals and industry
leaders. Only the strongest proposals with the best potential commercial outcome
are funded.
D-SIMLAB will be using the Grant to develop a novel “symbiotic simulation”
framework where a simulation model interacts with the real system it represents in
a symbiotic manner and in an iterative manner to mutually re-optimise to produce
the best outcome possible in both simulated and real systems. The project will bring
disruptive changes to both current methods and markets because for the first time
companies will be able to own and use a high visibility and high accuracy decision
support tool to optimise critical parameters of complex day to day operations that
are subject to random effects. The ability to adapt the underlying simulation model
in connection with simulation based optimisation at any decision point in time to
make continuous risk assessment possible will ensure that savings are real and
maintainable. As a result a traditionally “nice to have” technology for strategic and
tactical decision making will eventually be transformed into an indispensable “must
have” tool for operational decision making. D-SIMLAB plans to introduce this
technology for spare parts management in the aerospace industry and
semiconductor manufacturing through their flagship products D-SIMSPAIR and DSIMCON,
respectively.
D-SIMLAB, a company that spun off in 2006 from the Singapore Agency for Science,
Technology and Research (A*STAR), has achieved much over the last three years. As
a former incubatee of Exploit Technologies – the marketing and commercialisation
arm of A*STAR – D-SIMLAB has benefitted from the mentoring efforts and business
leads generated by its incubator. The company has ventured overseas in October
2008 by establishing a European subsidiary to better serve its expanding pool of
European clients, and also to support a pilot project with a leading German
semiconductor manufacturer. Additionally, as part of its future plan, D-SIMLAB has
secured a key MRO player and a major semiconductor company as lead customers
for the specific purposes of the proposal under TECS Grant. D-SIMLAB’s founding
team consisting of Dr. Peter Lendermann, Gan Boon Ping and Dr. Nirupam Julka,
were conferred the A*STAR Scientist Entrepreneur Award 2009 for successfully
commercialising their research.
Commenting on the successful Grant Award, Dr. Peter Lendermann, CEO and Co-
Founder of D-SIMLAB said, “The TECS POV award is an independent endorsement of
our technology development and commercialisation plans in the Aerospace MRO
and Semiconductor Manufacturing industry. The development of this Symbiotic
Simulation framework and its implementation in the industry will propel the value
proposition of D-SIMLAB to the industry.”
Mr Boon Swan Foo, Chairman of D-SIMLAB and Executive Chairman of Exploit
Technologies said, “Receiving the competitive TECS Grant is a strong testimony to
Exploit Technologies’ efforts in nurturing the young company; and in D-SIMLAB’s
excellent implementation of its marketing and development plan, which is backed by
robust A*STAR technology. Exploit Technologies has worked very closely with DSIMLAB
since its infancy days when the founders were still researchers with the
A*STAR’s Singapore Institute of Manufacturing Technology (SIMTech). Recognising
D-SIMLAB’s market potential, we have at the on start helped in evolving its business
plan, raising funds, opening doors to business opportunities, providing mentoring
services and lending our support to the company’s daily operations.
“We are heartened that D-SIMLAB has brought to fruition our efforts through its
early successes in securing major customers and venturing overseas; all these
despite the bleak economic conditions. Exploit Technologies remains committed in
our quest to incubate more of such companies like D-SIMLAB; so as to develop a
robust pipeline of promising made in Singapore technologies and start-ups.”
The company’s focus on long term development plan has also attracted substantial
investment last year from Imprimatur Capital, an international investor in
technology backed businesses. “D-SIMLAB is an exciting and rapidly growing
company with best of breed technology and a great track record of execution in their
target markets and we are extremely happy to have made our investment in the
business. They are also a showcase for Singapore and what it can offer in terms of early stage growth technology businesses. We are confident their recent accolades
will spur them on to greater success and look forward confidently to them realising
their full potential,” said Andy Bottomley, Executive Director of Imprimatur Capital,
UK.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.